ASCLF (Ascletis Pharma) Tariff Resilience Score: 6/10 (As of Jul. 13, 2026)


ASCLF Ascletis Pharma Inc ASCLF
38 GF Score
Price $1.44
GF Value $0.02
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Ascletis Pharma Tariff Resilience Score?

Ascletis Pharma ASCLF -4.00% 38 Tariff Resilience Score is 6 as of Jul. 13, 2026. GuruFocus rates ASCLF with a GF Score™ of 38/100 and a GF Value™ of $0.02 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,370 Biotechnology companies, Ascletis Pharma ranks better than 75.99% on this metric.

Ascletis Pharma has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Ascletis Pharma has Ascletis Pharma, based in China, exports pharmaceuticals globally. While tariffs on medical products are generally low, supply chain dependencies on raw materials can pose risks. The company can leverage alternative suppliers to mitigate some impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Ascletis Pharma might have Average Resilient.

Ascletis Pharma  (OTCPK:ASCLF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Ascletis Pharma Tariff Resilience Score Related Terms

ASCLF vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Ascletis Pharma's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascletis Pharma Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascletis Pharma's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Ascletis Pharma's Tariff Resilience Score falls into.


ASCLF
38GF Score
Ascletis Pharma Inc ASCLF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Ascletis Pharma (ASCLF) has a Tariff Resilience Score of 6 as of Jul. 13, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Ascletis Pharma ranks #329 out of 1370 companies in the Biotechnology industry, placing it in the top 24%.
Is Ascletis Pharma's Tariff Resilience Score too high?
Ascletis Pharma's current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Ascletis Pharma's value of 6 is 50% above this industry median. Based on the distribution chart, Ascletis Pharma ranks #329 out of 1370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ascletis Pharma has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ascletis Pharma's Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascletis Pharma ranks #329 out of 1370 companies for Tariff Resilience Score. This places Ascletis Pharma in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Ascletis Pharma's value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascletis Pharma's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascletis Pharma's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascletis Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ascletis Pharma (ASCLF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $1.44 — trading 7100% above its estimated fair value. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Ascletis Pharma's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Ascletis Pharma (ASCLF), the current Tariff Resilience Score is 6 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ascletis Pharma (ASCLF) Overvalued in 2026?

Based on GuruFocus' analysis, Ascletis Pharma stock appears to be overvalued. The current stock price of $1.44 is trading 7100% above its estimated GF Value™ of $0.02. GuruFocus considers Ascletis Pharma to be Significantly Overvalued.

Key valuation signals for ASCLF:

  • Tariff Resilience Score: 6
  • GF Value™: $0.02 vs. price of $1.44 (7100% above fair value)
  • GF Score™: 38/100 with 5 warning signs
  • Industry Position: 50% above the Biotechnology median (#329 of 1370)

No single metric tells the full story. See the ASCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ascletis Pharma Business Description

Other Exchanges 01672:Hong Kong2VJ:Germany
Address No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Wanchai, HKG, 311200
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. The drug candidates of the company in the pipeline in their different stages of development such as ASC30, ASC47, ASC39, ASC36i, ASC35, ASC50, and among others.
38GF Score

Get the complete analysis for ASCLF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.44
Price
$0.02
GF Value